Form 4: Bio-Rad Executive Acquires Company Stock
Statement of Changes in Beneficial Ownership
Courtney C. Enloe, EVP, General Counsel & Secretary of Bio-Rad Laboratories, Inc., acquired shares through the vesting of restricted stock units and participation in the Employee Stock Purchase Plan.
Summary
- Courtney C. Enloe, Executive Vice President, General Counsel & Secretary of Bio-Rad Laboratories, Inc., reported a transaction involving company stock.
- On April 24, 2026, 186 shares of Bio-Rad A Common Stock were acquired upon the vesting of restricted stock units.
- Additionally, 77 shares of Bio-Rad A Common Stock were disposed of at a price of $287.84 per share.
- The filing also notes the acquisition of shares through the Bio-Rad Employee Stock Purchase Plan on September 30, 2025 (6.1520 shares) and December 31, 2025 (5.6340 shares).
- As of the reporting date, Enloe beneficially owns 749.777 shares of Bio-Rad A Common Stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine stock transactions related to executive compensation and employee benefit plans, with no significant indication of positive or negative performance.
Positives
- Acquisition of company stock by a key executive through the vesting of restricted stock units, indicating alignment with company performance.
- Continued participation in the Employee Stock Purchase Plan, demonstrating ongoing investment in the company by management.
Negatives
- Disposal of 77 shares of Bio-Rad A Common Stock at $287.84 per share.
Future Outlook
The filing does not contain forward-looking statements or guidance.
Industry Context
StockSavvy.ai notes that Form 4 filings, like this one from Bio-Rad Laboratories, are standard disclosures for insider transactions. They provide transparency into the buying and selling activities of company executives and directors, which can be a signal to the market, though individual transactions should be viewed in the context of overall compensation and financial planning.
Stakeholder Impact
- Shareholders: The filing provides transparency into executive stock ownership and transactions, which can inform investment decisions.
- Employees: The mention of the Employee Stock Purchase Plan highlights a benefit available to employees.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Acquisition of shares under the Bio-Rad Employee Stock Purchase Plan. |
| 12/31/2025 | Acquisition of shares under the Bio-Rad Employee Stock Purchase Plan. |
| 04/24/2026 | Vesting of restricted stock units and acquisition of Bio-Rad A Common Stock. |
| 04/27/2026 | Date of signature for the Form 4 filing. |
Keywords
Bio-Rad Laboratories, BIO, BIO.B, Form 4, Insider Trading, Stock Vesting, Employee Stock Purchase Plan, Executive Compensation, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.